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Background: Amorphous silica nanoparticles (SiNP) can be used in medical technologies 
and other industries leading to human exposure. However, an increased number of studies 
indicate that this exposure may result in cardiovascular inflammation and damage. A high ratio 
of nitric oxide to peroxynitrite concentrations ([NO]/[ONOO-]) is crucial for cardiovascular 
homeostasis and platelet hemostasis. Therefore, we studied the influence of SiNP on the platelet 
[NO]/[ONOO-] balance and platelet aggregation.
Methods: Nanoparticle–platelet interaction was examined using transmission electron 
microscopy. Electrochemical nanosensors were used to measure the levels of NO and ONOO- 
released by platelets upon nanoparticle stimulation. Platelet aggregation was studied using light 
aggregometry, flow cytometry, and phase contrast microscopy.
Results: Amorphous SiNP induced NO release from platelets followed by a massive stimulation 
of ONOO- leading to an unfavorably low [NO]/[ONOO-] ratio. In addition, SiNP induced an 
upregulation of selectin P expression and glycoprotein IIb/IIIa activation on the platelet   surface 
membrane, and led to platelet aggregation via adenosine diphosphate and matrix metalloprotei-
nase 2-dependent mechanisms. Importantly, all the effects on platelet aggregation were inversely 
proportional to nanoparticle size.
Conclusions: The exposure of platelets to amorphous SiNP induces a critically low 
[NO]/[ONOO-] ratio leading to platelet aggregation. These findings provide new insights into 
the pharmacological profile of SiNP in platelets.
Keywords: amorphous silica nanoparticles, nanotoxicology, nitric oxide, peroxynitrite, platelet 
aggregation
Introduction
It is increasingly recognized that engineered amorphous silica nanoparticles (SiNP) 
may have important implications for vascular homeostasis. We have recently demon-
strated the ability of SiNP to induce endothelial cell dysfunction linked to increased 
peroxynitrite (ONOO-) production.1 As human blood platelets along with endothelium 
play a critical role in vascular homeostasis, we have now examined the biocompatibility 
of amorphous SiNP (10 nm, 10SiNP; 50 nm, 50SiNP; 150 nm, 150SiNP; 500 nm, 
500SiNP) with human platelets.
The vascular NO, synergistically with prostacyclin, inhibits platelet activation 
and aggregation.2–5 This vasorelaxant and platelet regulator is essential for vascular 
homeostasis and an impairment of NO bioavailability is one of the earliest events in 
vascular diseases.6,7 Superoxide anion reacts rapidly with NO producing ONOO-, 
a major component of oxidative stress, rapidly decreasing NO bioavailability.8 
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A high ONOO- production and depleted NO availability 
resulting in a low ratio of maximal NO to maximal ONOO- 
concentrations ([NO]/[ONOO-]) can be accurately used as an 
indicator of nitroxidative/oxidative stress and dysfunction of 
the cardiovascular system.1,9–11 The high [NO]/[ONOO-] bal-
ance is essential for maintaining platelet regulation, as high 
amounts of ONOO- counteract the platelet-inhibitory effects 
of NO leading to platelet activation and aggregation.12
In the current studies, a direct release of NO and ONOO- 
during nanoparticle-platelet interactions was measured 
electrochemically by nanosensors. The NO generation by 
platelets was followed by a greater ONOO- production lead-
ing to a low [NO]/[ONOO-] ratio. Indeed, we demonstrated 
that amorphous SiNP induced activation of the glycoprotein 
IIb/IIIa (GPIIb/IIIa) and expression of the selectin P (SELP) 
on the platelet surface membrane leading to platelet activation 
and aggregation. The activation of GPIIb/IIIa is triggered 
off by the release of major platelet activators that mediate 
pathways of aggregation such as thromboxane A2 (TXA2),13 
adenosine diphosphate (ADP)14 and matrix metalloproteinase 
2 (MMP2)15 which amplify aggregation. Our studies showed 
that SiNP induce platelet aggregation via stimulation of ADP 
and MMP2 released from platelets.
Materials and methods
Reagents
All reagents were purchased from Sigma-Aldrich (Arklow, 
Ireland) unless otherwise indicated. Engineered amorphous 
SiNP with different sizes (10 nm, 50 nm, 150 nm, and 
500 nm) were purchased from Polysciences (Eppelheim, 
Germany).
Zeta potential measurement
The zeta potentials of all the SiNP were determined by 
a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK). Measurements were performed six times for each 
particle size (100 µg/mL in ultrapure water) at room 
temperature.
Transmission electron microscopy  
(TEM) of SiNP
Nanoparticle suspensions (10 µg/mL in ultrapure water) 
were examined by a JEM 2100 transmission electron micro-
scope (JEOL, Herts, UK). The diameter of 100 nanoparticles 
of each size on three TEM micrographs was measured by 
ImageJ an open-source, Java-based imaging software (http://
rsbweb.nih.gov/ij/).
Isolation of human platelets
Blood was obtained from healthy volunteers who had 
not taken any drugs known to affect platelet function for 
2 weeks prior to the study. Washed platelets were obtained as 
described previously.16 Briefly, blood was collected and anti-
coagulated using trisodium citrate (3.15% w/v; 9:1 v/v). The 
citrated blood was centrifuged at room temperature to prepare 
platelet-rich plasma (PRP). Washed platelets were prepared 
by centrifugation of PRP, containing prostacyclin at room 
temperature. Following isolation, platelets were resuspended 
in prostacyclin-free Tyrode’s salt solution. Washed platelet 
concentrations were adjusted using Tyrode’s salt solution to 
a final concentration of 2.5 × 108 platelets per milliliter.
Aggregation studies
Immediately before use, commercial stock suspensions of 
SiNP were sonicated for 2 minutes and nanoparticle disper-
sions in Tyrode’s salt solution were prepared by serial dilu-
tion from these stock suspensions by vortexing. We tested 
the effect of different SiNP (10SiNP, 50SiNP, 150SiNP and 
500SiNP) at different concentrations (1 to 200 µg/mL).
Platelets were incubated for 2 minutes at 37°C in a whole 
blood/optical lumi-aggregometer (model 700; Chrono-Log, 
Manchester, UK) prior to the addition of nanoparticles 
to test spontaneous aggregation. Platelet aggregation was 
studied for 15 minutes against blanks (Tyrode’s salt solution) 
  containing the same particle concentration as the test tubes. 
Collagen was used as a positive control for platelet aggrega-
tion   studies. Aggregation data was analyzed by Chrono-Log 
AGGRO-LINK 8 sofware.17–19
Selective platelet aggregation inhibitors (acetylsalicylic 
acid [ASA], phenanthroline, and apyrase) were added to test 
tubes. After 1 minute, SiNP were added to the appropriate 
test tubes.
TEM of human platelets
Platelet aggregation was terminated at 30% maximal 
response, as determined using an aggregometer, in platelets 
exposed to 10 µg/mL 10SiNP. Unstimulated (resting) platelets 
were also prepared. Samples were fixed by mixing them with 
an equal volume of 3% glutaraldehyde in 0.1 M phosphate 
buffer for 1.5 hours at room temperature. After primary fixa-
tion, samples were centrifuged and pellets washed six times 
with phosphate buffer. Then, pellets were post-fixed with 2% 
osmium tetroxide in phosphate buffer for 30   minutes. Pellets 
were then dehydrated in a series of graded ethanol solution, 
infiltrated and embedded in agar 100 epoxy resin, using pro-
pylene oxide as a transitional fluid. Next, ultrathin sections 
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were cut from dried blocks with a diatom diamond knife on 
a LKB ULTRATOM III (LKB, Uppsala, Sweden), stained 
with 0.5% aqueous uranyl acetate followed by Reynold’s 
lead citrate. Finally, sections were examined by a JEM 2100 
transmission electron microscope.
Measurement of NO and ONOO- 
concentrations using nanosensors
Concurrent NO and ONOO- measurements were performed 
with electrochemical nanosensors (diameter: 300–500 nm). 
The designs are based on previously developed and well-
characterized chemically modified carbon-fiber technol-
ogy.20,21 Each of the sensors was made by depositing a 
sensing material on the tip of the carbon fiber: conductive 
film of polymeric nickel (II) tetrakis (3-methoxy-4hydroxy-
phenyl) porphyrinic for the NO sensor20 and a polymeric 
film of Mn (III)–paracyclophanyl-porphyrin for the ONOO- 
  sensor22. Amperometry was used to measure changes in NO 
and ONOO- concentrations from its basal level with time 
(detection limit of 1 nM and resolution time ,10 µs for 
each sensor). Linear calibration curves were constructed for 
each sensor from 5 nM to 3 µM before and after measure-
ments with aliquots of NO and ONOO- standard solutions, 
respectively. Measurements were performed into platelet 
suspensions. We tested the effect of different SiNP (10SiNP, 
50SiNP, 150SiNP, and 500SiNP) at different concentrations 
(1 to 200 µg/mL).
Selectin P and gPIIb/IIIa analyses  
by flow cytometry
Flow cytometry was performed using a FACSArrayTM bioan-
alyzer (Becton, Dickinson and company [BD], Oxford, UK) 
on single stained platelet samples as described previously.17,23 
Briefly, to analyze SELP expression, platelet aggregation was 
terminated at 30% maximal response, as determined using an 
aggregometer, in platelet exposed to different SiNP (10SiNP, 
50SiNP, 150SiNP, and 500SiNP) at different concentrations 
(1 to 200 µg/mL). Platelet suspensions and anti-selectin-P 
antibody (BD) were then mixed and incubated in the dark 
at room temperature for 5 minutes. Platelets were identified 
by forward and side scatter signals, and 10,000 platelet-
specific events were analyzed by the flow cytometer for 
fluorescence.
To analyze GPIIb/IIIa activation, platelet aggregation 
was terminated at 30% maximal response, as determined 
using an aggregometer, in platelets exposed to different SiNP 
as above. Platelet suspensions and PAC-1 antibody (BD) 
were mixed and incubated in the dark at room temperature 
for 15 minutes. Afterwards, an APC Rat Anti-Mouse IgM 
(secondary antibody) was added and samples incubated in 
the dark at room temperature for another 15 minutes. Platelets 
were identified by forward and side scatter signals, and 10,000 
platelet-specific events were analyzed by the flow cytometer 
for fluorescence.
Nonactivated and activated platelets were gated so as not 
to analyze platelet aggregates. Silica nanoparticles were not 
detected by the bioanalyzer.
Statistical analyses
All data are presented as group of means ± standard error 
of the mean of n . 3. Statistical analysis of the mean differ-
ence between multiple groups was determined by one-way 
ANOVA followed by Tukey-Kramer multiple comparison 
tests; and between two groups by two-tailed Student’s t-tests. 
The alpha level for all tests was 0.05. A P value , 0.05 was 
considered to be statistically significant. All statistical   analyses 
were performed using GraphPad Prism (version 5.00 for 
Windows; GraphPad Software, San Diego, CA) and Origin 
(version 6.1 for Windows; OriginLab, Northampton, MA).
Results
Nanoparticle characterization
In order to confirm the commercially-provided nanoparticle 
size, we used TEM to measure the size of SiNP. The TEM anal-
ysis of 10SiNP, 50SiNP, 150SiNP, and 500SiNP resulted in 
sizes of 10.50 ± 0.19 nm, 52.67 ± 0.66 nm, 148.20 ± 2.19 nm, 
and 495.90 ± 5.87 nm, respectively.1 Furthermore,   Zetasizer 
reported high negative zeta   potentials (more negative 
than -30 mV) for all SiNP tested in ultrapure water.1
Silica nanoparticle–platelet interaction
We studied nanoparticle–platelet interactions and uptake 
using TEM (Figure 1). Electron micrographs showed 
amorphous SiNP forming agglomerates. These agglomer-
ates were located within platelet aggregates, dispersed 
among platelets and interacting with the plasma membrane 
(  Figure 1B–D). Nanoparticles also internalized and distrib-
uted into the platelet cytoplasm (Figure 1C and D). We also 
observed degranulated platelets indicating platelet activation 
(  Figure 1C and D).
Silica nanoparticles induce  
a [NO]/[ONOO-] imbalance in platelets
Using electrochemical nanosensors, we examined in situ, 
real-time dynamic interaction of amorphous SiNP with 
human platelets by measuring directly NO and ONOO- 
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concentrations in a platelet suspension. We demonstrated 
with time resolution better than 10 µs that after collision 
with platelets, these nanoparticles rapidly stimulated NO 
release (Figure 2B) followed by a greater production of 
ONOO-. An increased ONOO- production was observed 
when nanoparticle concentration was increased and size 
decreased (Figure 2C). The exposure of human platelets 
to SiNP induced an unfavorable shift of the ratio of [NO]/
[ONOO-], as nanoparticle size decreased. Indeed, 10 µg/mL 
10SiNP induced a greater decrease in [NO]/[ONOO-] than 
an equal concentration of 50SiNP (Figure 2D). Moreover, 
50SiNP (100 µg/mL) induced a lower ratio than an equal 
concentration of larger nanoparticles (Figure 2E).
Silica nanoparticles induce platelet 
aggregation
We studied the ability of SiNP to induce platelet   aggregation. 
Our results demonstrate that amorphous SiNP induce acti-
vation of GPIIb/IIIa as well as expression of SELP in the 
platelet surface membrane (Figure 3A and B). Importantly, 
platelet receptor activation and expression was inversely 
proportional to nanoparticle size and directly proportional 
to particle concentration. Indeed, the smallest nanoparticles 
(10SiNP) induced GPIIb/IIIa activation and SELP expression 
when used at a low concentration (10 µg/mL). In contrast, 
an equal concentration of larger nanoparticles (50SiNP, 
150SiNP, and 500SiNP) did not influence platelet receptors. 
However, when used at a high concentration (100 µg/mL), 
50SiNP induced both GPIIb/IIIa activation and SELP 
  expression. Moreover, 200 µg/mL 150SiNP and 500SiNP 
induced SELP expression.
Furthermore, we demonstrated that amorphous SiNP 
directly induce platelet aggregation and that this effect is 
greater when nanoparticle size decreases and particle concen-
tration increases (Figure 3C). Indeed, 10SiNP induced plate-
let aggregation when used at a concentration of 10 µg/mL 
or higher. Also, 50SiNP and 150SiNP induced platelet 
aggregation when used at a concentration of 100 µg/mL 
and 200 µg/mL, respectively. However, 500SiNP did not 
induce platelet aggregation even when used at a very high 
concentration of 200 µg/mL.
Knowing that 10SiNP at 10 µg/mL were able to induce 
platelet aggregation, further experiments with selective inhibi-
tors of the pathways leading to platelet aggregation mediated 
AB
gr SiNP
D
SiNP
SiNP
C
Figure 1 Amorphous SiNP interact with human platelets. As shown by TEM, after exposure of human platelets to 10SiNP (10 µg/mL), nanoparticles rapidly interacted with 
the platelet surface membrane (B) and induced aggregation (C and D). Unstimulated (resting) platelets were also presented (A).
Notes: Scale bars represent 500 nm in A, C, and D; and 100 nm in B.
Abbreviations: SiNP, silica nanoparticles; gr, platelet granule; TEM, transmission electron microscopy.
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by TXA2 (ASA), ADP (apyrase), and MMP2 (phenanthroline) 
were carried out to characterize the mechanism of SiNP-induced 
platelet aggregation (Figure 3D). Our results show that incu-
bation of platelets with both phenanthroline and apyrase, but 
not ASA, prior to their exposure to nanoparticles, inhibited 
nanoparticle-induced platelet aggregation (Figures 3D and 4).
Discussion
Platelets and endothelial cells are crucial for the correct 
maintenance of vascular homeostasis. To exert their function, 
platelets survey the vascular system and adhere where altera-
tions of the endothelial cell lining, accompanied or not by 
exposure of subendothelial matrix components, are   detected.24 
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Figure 2 Amorphous SiNP induce NO and ONOO- production and unfavorably shift the [NO]/[ONOO-] balance in human platelets. (A) Representative recordings of NO 
and ONOO- measured in situ by specific nanosensors after the addition of 10 µg/mL 10SiNP to the platelet suspension (2.5 × 108 platelets per milliliter). (B and C) Maximal 
NO (B) and ONOO- (C) release from a single platelet following stimulation by SiNP: 10SiNP (■), 50SiNP (□), 150SiNP (●), 500SiNP (○). (D and E) The [NO]/[ONOO-] 
ratio of the maximal NO and ONOO- concentrations measured upon stimulation of platelets by SiNP at 10 µg/mL (D) and 100 µg/mL (E).
Notes: All values are mean ± standard error of the mean (SEM) of n = 4. One-way ANOVA and Tukey-Kramer multiple comparison tests were used for analysis (B and C). 
All values are mean ± SEM of n = 4. Two-tailed Student’s t-test: ***P , 0.001 compared with 10 µg/mL 10SiNP (D). One-way ANOVA and Tukey-Kramer multiple comparison 
test: ***P , 0.001 compared with 100 µg/mL 50SiNP (E).
Abbreviations: SEM, standard error of the mean; SiNP, silica nanoparticles.
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On the other hand, by the secretion or surface expression of a 
series of specific molecules (NO,   prostacyclin), endothelial 
cells ensure that under normal conditions blood flow is appro-
priately regulated and that intravascular platelet activation 
and blood coagulation are avoided.
The deleterious effect of SiNP on endothelial cells found 
in our previous work1 prompted us therefore to study the 
effect of SiNP on human platelets. In this current study, we 
found that amorphous SiNP when interacting with human 
blood platelets have the ability to stimulate the release of 
NO and to a greater extent ONOO- leading to a low [NO]/
[ONOO-] ratio that correlated well with the SiNP-induced 
platelet aggregation. Indeed, we observed that SiNP 
stimulated GPIIb/IIIa activation and SELP expression and 
led to platelet aggregation via ADP- and MMP2-dependent 
mechanisms. All of these effects augmented with increased 
nanoparticle concentration, but were inversely proportional to 
the size of SiNP. In fact, the smallest SiNP (10 nm) induced 
the most severe effects on platelets. Recently, our studies on 
the effects of amorphous SiNP on human endothelial cells 
also reported the role of the [NO]/[ONOO-] ratio in the 
nanoparticle-induced endothelial inflammatory and cytotoxic 
responses.1
Amorphous SiNP have a noncrystalline structure, a high 
surface-area-to-volume ratio and a large negative surface charge. 
A high surface-area-to-volume ratio, which decreases in the 
opposite direction to size, favors the formation of the “protein 
corona” with fundamental significance for   bionanointeractions. 
The “protein corona” along with fluid characteristics and par-
ticle surface area and zeta potentials can affect the formation 
of nanoparticle agglomerates in the biological environment and 
may influence nanoparticle toxicity.25,26
Our TEM study shows that SiNP interacted with the 
platelet surface membrane, internalized and distributed within 
the platelet cytoplasm. The interaction of SiNP with platelet 
surface membranes raised the possibility that nanoparticles 
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Figure 3 Amorphous SiNP upregulate surface receptors and induce platelet aggregation. Nanoparticles induce gPIIb/IIIa activation (A), SELP expression (B), and platelet 
aggregation (C). The use of phenanthroline (Phen) and apyrase (Apyr), but not acetylsalicylic acid (ASA), inhibits 10SiNP-induced platelet aggregation (D). A mixture of these 
three inhibitors also inhibited nanoparticle-induced platelet aggregation (D). Collagen (Coll) was used as a positive control for platelet aggregation. The gPIIb/IIIa activation 
(A) and SELP expression (B) induced by each nanoparticle treatment is expressed relative to unstimulated (resting) platelets.
Notes: All values are mean ± SEM of n = 4. One-way ANOVA, Tukey-Kramer post test: *P , 0.05; **P , 0.01; ***P , 0.001 compared with resting platelets (RP) (A–C). 
One-way ANOVA, Tukey-Kramer post test: ^^P , 0.01; ^^^P , 0.001 compared with 10 µg/mL 10SiNP (D).
Abbreviations: SEM, standard error of the mean; SiNP, silica nanoparticles.
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can affect calcium channels as well as the endothelial nitric 
oxide synthase (eNOS) that is associated with caveolae.27 
Indeed, there is convincing evidence that modulation of 
mechanosensitive ion channels involves NO and ONOO-.28 
Therefore, we hypothesized that amorphous SiNP collide with 
the platelet surface membrane leading to opening of calcium 
channels, and eventually, uncoupling of eNOS. The kinetics of 
the penetration of the platelet membrane by SiNP most likely 
involved a flux of calcium ions into the cytoplasm.29 Therefore, 
SiNP are likely to stimulate a calcium-dependent NO release 
in human platelets. The process of increased and prolonged 
NO production leads to depletion of enzymatic substrates 
and cofactors, and eventually, uncoupling of eNOS.30 The 
uncoupled eNOS can generate superoxide10 which can rapidly 
react with NO to produce ONOO- and change critically the 
balance of [NO]/[ONOO-]. At high level of cytoprotective 
NO and/or low level of cytotoxic ONOO-, this ratio is high 
(.2.0) indicating coupled eNOS and normal endothelial 
and platelet function. A low ratio (,1.0) is associated with 
uncoupled eNOS, dysfunctional cardiovascular system and 
high nitroxidative/oxidative stress.1,9,10 Our current experimen-
tal results support this hypothesis and show that amorphous 
SiNP unfavorably shift the [NO]/[ONOO-] balance to low 
levels. There is convincing evidence that platelet aggregation 
is favored by nitroxidative/oxidative stress induced by ONOO-
.11,12 Indeed, platelet-derived and exogenous ONOO- induce 
TXA2 formation,31 nitration of  tyrosine-containing proteins,32 
SELP expression and GPIIb/IIIa activation.12 The activation 
of GPIIb/IIIa (a change from the low- to high-affinity con-
formation) and translocation of SELP to the platelet surface 
membrane is crucial for platelet aggregation to occur.33,34 
Indeed, GPIIb/IIIa is the major platelet surface transmembrane 
receptor and it plays an important role in platelet aggrega-
tion.35 In addition, platelets contain a pool of this glycoprotein 
stored in α-granules.36 Furthermore, SELP, that is also stored 
in platelet α-granules, mediates platelet-leukocyte aggrega-
tion since it is rapidly translocated to the surface upon platelet 
activation.37 Our studies demonstrate that SiNP have the ability 
to induce GPIIb/IIIa activation and SELP expression on the 
platelet surface membrane leading to platelet aggregation. 
Interestingly, carbon nanoparticles, including nanotubes, have 
a similar ability.38,39 The activation of GPIIb/IIIa is triggered 
off by the release of major platelet activators that mediate 
pathways of aggregation such as TXA2,13 ADP,14 and MMP215 
which amplify aggregation. In fact, we have previously shown 
that MMP2 translocates to the platelet surface during platelet 
aggregation.40 Indeed, it has been also demonstrated the inter-
action of MMP2 with the integrin αIIβIII on the platelet mem-
brane.41 We demonstrate here that SiNP can stimulate platelet 
aggregation via ADP- and MMP2-  dependent   mechanisms. 
Figure 4 Amorphous SiNP induce platelet aggregation. Platelets were exposed to 10 µg/mL 10-nm SiNP in the absence (C) or present of inhibitors of platelet aggregation 
(D–G). Unstimulated (resting) platelets (A) and platelet aggregation induced by collagen (B) are also shown. Previous to the exposure to 10SiNP, platelets were incubated 
with acetylsalicylic acid (D), phenanthroline (E), apyrase (F) and a mixture of these three inhibitors (G).
Note: Scale bars represent 100 µm.
Abbreviation: SiNP, silica nanoparticles.
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However, in contrast to agonist-induced aggregation which 
can be   abolished by combination of ASA, apyrase, and 
phenanthroline,15 SiNP-induced aggregation is not completely 
dependent on the release of TXA2, ADP, and MMP2. Interest-
ingly, nanoparticles can directly interact with proteins and ion 
channels and these effects can also contribute to the profile 
of SiNP actions on platelets.42,43
In conclusion, engineered amorphous SiNP penetrated 
the platelet plasma membrane and stimulated a rapid and 
prolonged NO release leading to eNOS uncoupling, ONOO- 
over-production and eventually, a low [NO]/[ONOO-] ratio and 
high nitroxidative/oxidative stress. The unfavorable situation, 
thus produced, favored receptors activation (GPIIb/IIIa) and 
expression (SELP) on the platelet surface membrane leading to 
platelet activation and aggregation. Furthermore, SiNP-induced 
platelet aggregation is mediated via the MMP2 and ADP path-
ways. Importantly, these effects were all inversely proportional 
to the amorphous SiNP size and directly proportional to nano-
particle concentration. These findings, along with our study on 
endothelial cells,1 conclusively highlight the importance of NO/
peroxynitrite imbalance in the pathomechanism of nanotoxico-
logical effects of amorphous SiNP with profound implications 
in the disruption of vascular homeostasis.
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